$1,318.00
This Market Spotlight report covers the Hereditary Angioedema market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Hereditary Angioedema (HAE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 C1-INH concentrates
9 Plasma-derived C1-INH (pdC1-INH)
9 Recombinant C1-INH (rhC1-INH)
9 Kallikrein inhibitors
10 Bradykinin receptor antagonist
11 EPIDEMIOLOGY
15 MARKETED DRUGS
18 PIPELINE DRUGS
22 RECENT EVENTS AND ANALYST OPINION
22 IONIS PKK-LR for HAE (March 29, 2021)
23 Garadacimab for HAE (March 1, 2021)
24 Orladeyo for HAE (March 1, 2021)
25 KVD900 for HAE (February 9, 2021)
28 KEY UPCOMING EVENTS
29 KEY REGULATORY EVENTS
29 SMC Recommends BioCryst’s Orladeyo To Prevent HAE Attacks
29 BioCryst’s Orladeyo Wins Recommendation For Use In England
29 BioCryst & Celgene Suffer English Funding Setback For Rare Disease Drugs
30 New EU Approvals
30 Icatibant Accord Among Eight New Products To Win EMA Nod
30 Rare Disease Approval For Takeda
31 PROBABILITY OF SUCCESS
32 LICENSING AND ASSET ACQUISITION DEALS
32 Pharming Signs License Agreement With NewBridge Pharmaceuticals
32 Pharming And Orchard Seek Stem Cell Solution To Hereditary Angioedema
33 REVENUE OPPORTUNITY
35 CLINICAL TRIAL LANDSCAPE
36 Sponsors by status
37 Sponsors by phase
39 BIBLIOGRAPHY
41 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in prevalent cases of HAE, 2019–28
18 Figure 2: Overview of pipeline drugs for HAE in the US
18 Figure 3: Pipeline drugs for HAE, by company
19 Figure 4: Pipeline drugs for HAE, by drug type
19 Figure 5: Pipeline drugs for HAE, by classification
23 Figure 6: IONIS PKK-LR for HAE (March 29, 2021): Phase II – ISIS 721744-CS2
27 Figure 7: KVD900 for HAE (February 9, 2021): Phase II – On-Demand Treatment
28 Figure 8: Key upcoming events in HAE
31 Figure 9: Probability of success in the autoimmune/immunology-other pipeline
35 Figure 10: Clinical trials in HAE
35 Figure 11: Top 10 drugs for clinical trials in HAE
36 Figure 12: Top 10 companies for clinical trials in HAE
36 Figure 13: Trial locations in HAE
37 Figure 14: HAE trials status
38 Figure 15: HAE trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of HAE, 2019–28
16 Table 2: Marketed drugs for HAE
20 Table 3: Pipeline drugs for HAE in the US
22 Table 4: IONIS PKK-LR for HAE (March 29, 2021)
23 Table 5: Garadacimab for HAE (March 1, 2021)
24 Table 6: Orladeyo for HAE (March 1, 2021)
25 Table 7: KVD900 for HAE (February 9, 2021)
33 Table 8: Historical global sales, by drug ($m), 2017–21
34 Table 9: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!